Findings of Research Misconduct, 64799-64800 [2014-25887]

Download as PDF Federal Register / Vol. 79, No. 211 / Friday, October 31, 2014 / Notices 64799 Docket # (FHFAID) Member City 13260 ............ 55342 ............ 55117 ............ 55245 ............ 55213 ............ 55118 ............ 4347 .............. 14623 ............ 16274 ............ 1925 .............. 16193 ............ 1528 .............. 16484 ............ 16506 ............ 921 ................ 55069 ............ 3903 .............. 10647 ............ 55077 ............ 3790 .............. 15949 ............ 9491 .............. 13484 ............ 15713 ............ Bank of Eastern Oregon ...................................................................................... Great Western Insurance Company .................................................................... Transportation Alliance Bank, Inc. ....................................................................... Granite Federal Credit Union ............................................................................... Cyprus Credit Union ............................................................................................. Great Northwest Credit Union .............................................................................. Riverview Community Bank ................................................................................. The Bank of Washington ..................................................................................... Fife Commercial Bank .......................................................................................... Olympia FS & LA ................................................................................................. TwinStar Credit Union .......................................................................................... First FS & LA of Port Angeles ............................................................................. Seattle Savings Bank ........................................................................................... Our Community Federal Credit Union ................................................................. Yakima FS & LA .................................................................................................. Solarity Credit Union ............................................................................................ Buffalo Federal Bank ........................................................................................... Hilltop National Bank ............................................................................................ Wyhy Credit Union ............................................................................................... Big Horn Federal Savings Bank .......................................................................... Oregon Trail Bank ................................................................................................ Rocky Mountain Bank .......................................................................................... RSNB Bank .......................................................................................................... Pinnacle Bank—Wyoming .................................................................................... Heppner ................................................ Ogden ................................................... Ogden ................................................... Salt Lake City ....................................... West Jordan .......................................... Aberdeen .............................................. Camas ................................................... Edmonds ............................................... Fife ........................................................ Olympia ................................................. Olympia ................................................. Port Angeles ......................................... Seattle ................................................... Shelton .................................................. Yakima .................................................. Yakima .................................................. Buffalo ................................................... Casper .................................................. Cheyenne .............................................. Greybull ................................................. Guernsey .............................................. Rock Springs ........................................ Rock Springs ........................................ Torrington .............................................. II. Public Comments To encourage the submission of public comments on the community support performance of Bank members, on or before November 17, 2014, each Bank will notify its Advisory Council, nonprofit housing developers, community groups and other interested parties in its district of the members of the Bank selected for this review cycle. 12 CFR 1290.2(b)(2)(ii). In reviewing a member for community support compliance, FHFA will consider any public comments it has received concerning the member. 12 CFR 1290.2(d). To ensure consideration by FHFA, comments concerning the community support performance of members selected for this review cycle must be submitted to FHFA, either by electronic mail to hmgcommunitysupportprogram@ fhfa.gov, or by fax to 202–649–4130, on or before December 15, 2014. Dated: October 27, 2014. Melvin L. Watt, Director, Federal Housing Finance Agency. [FR Doc. 2014–25970 Filed 10–30–14; 8:45 am] asabaliauskas on DSK5VPTVN1PROD with NOTICES BILLING CODE 8070–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: VerDate Sep<11>2014 18:51 Oct 30, 2014 Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Bijan Ahvazi, Ph.D., National Institutes of Health: Based on the report of an investigation conducted by the National Institutes of Health (NIH) and additional analysis by ORI in its oversight review, ORI found that Dr. Bijan Ahvazi, former Director of the Laboratory of X-ray Crystallography, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, engaged in research misconduct in research supported by the Intramural Program at NIAMS, NIH. ORI found that Respondent engaged in research misconduct by falsifying data related to or in the following published papers: 1. Ahvazi, B., Boeshans, K.M., Idler, W., Baxa, U., & Steinert, P.M. ‘‘Structural basis for the coordinated regulation of transglutaminase 3 by guanine nucleotides and calcium/ magnesium.’’ J. Biol. Chem. 279(8):7180–92, 2004 Feb 20 (withdrawn) (hereinafter ‘‘JBC 2004a’’) 2. Ahvazi, B., Boeshans, K.M., & Steinert, P.M. ‘‘Crystal structure of transglutaminase 3 in complex with BMP: Structural basis for nucleotide specificity.’’ J. Biol. Chem. 279:26716– 25, 2004 (withdrawn) (hereinafter ‘‘JBC 2004b’’) 3. Ahvazi, B., Boeshans, K.M., Idler, W.,& Cooper, A.J.L. ‘‘Crystal structure of transglutaminase 3-cystamine complex: Binding of two cystamines to the nucleotide-binding pocket. M6:06060, SUMMARY: Jkt 235001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 State OR UT UT UT UT WA WA WA WA WA WA WA WA WA WA WA WY WY WY WY WY WY WY WY Submitted to J. Biol. Chem., 2006 (rejected) (hereinafter ‘‘JBC 2006’’). Specifically, ORI finds that Respondent: 1. Falsely labeled Figure 3A in JBC 2004b representing an isothermal calorimetric titration (ITC) experiment using guanine monophosphate (GMP) and transglutaminase 3 (TGase 3) when the figure was actually a relabeled version of an unrelated experiment that Respondent previously published as Figure 1A in JBC 2004a. 2. falsified Figure 4B, Figure 4C, and Figure 6D in JBC 2004b and Figure 5E in JBC 2006, by altering the original data in the following ways to represent the desired experiment: a. Falsified Figure 4B in JBC 2004b, by adding multiple data points to titration curves for four different concentrations of TGase 3 bound by different concentrations of tagged GTPgS and deleting two (2) outlying data points from one of the curves b. falsified Figure 4C in JBC 2004 b, representing a competition assay for the release of tagged GTPgS bound to TGase 3, by (1) falsely claiming that the release of the tagged nucleotide occurred with the addition of untagged GMP, when the result was from an assay using untagged GDP, (2) adding additional data points onto the titration curves, and (3) altering the scale of the abscissa c. falsified Figure 6D in JBC 2004b, by using the false Figure 4B to also represent an additional competition experiment using unmodified nucleotide analog compounds and E:\FR\FM\31OCN1.SGM 31OCN1 64800 Federal Register / Vol. 79, No. 211 / Friday, October 31, 2014 / Notices asabaliauskas on DSK5VPTVN1PROD with NOTICES ATP; specifically, Respondent (1) falsified the units and labels of the axes, (2) falsified the labels of the curves, and (3) vertically inverted the curves d. falsified Figure 5E in the JBC 2006 manuscript, representing a competition experiment for the release of tagged GTPgS bound to TGase 3 with the addition of cystamine, when the actual experiment was a competition experiment with the addition of untagged nucleotides. Dr. Ahvazi has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of two (2) years, beginning on October 7, 2014: (1) To have his U.S. Public Health Service (PHS) research supervised and to notify any employer(s)/institution(s) at which he may participate in PHS funded projects of the terms of his supervision; Respondent agrees that prior to the submission of an application for PHS support for a research project on which the Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent’s duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent’s research; Respondent agrees that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agrees to maintain responsibility for compliance with the agreed upon supervision plan; (2) that any institution employing him to work on PHS-supported projects shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHSsupported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and (3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite VerDate Sep<11>2014 18:51 Oct 30, 2014 Jkt 235001 750, Rockville, MD 20852, (240) 453– 8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2014–25887 Filed 10–30–14; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Intent To Award Ebola Response Outbreak Funding to Eligible Ministries of Health and Their Bona Fide Agents Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: This notice provides public announcement of CDC’s intent to award Ebola appropriations to select Ministries of Health and their bona fide agents for response to the Ebola outbreak funding. This award was proposed in Fiscal Year (FY) 2015 under funding opportunity announcement GH14–1418, ‘‘Protecting and Strengthening Public Health Impact, Systems, Capacity, and Security.’’ This notice replaces the Notice of Intent to award Ebola Response outbreak funding to eligible Ministries of Health and their bona fide agents which was published on October 22, 2014 (79 FR 63126, October 22, 2014). CDC is correcting the application date, award dates, amount of funding available, and one of the points of contact. SUMMARY: Catalogue of Federal Domestic Assistance Number (CFDA): 93.318. Authority: Public Health Service 301(a) and 307 as amended [42 U.S.C 241 and 242l]. Multiple awards may be awarded to grantees totaling $300,000 to $1,500,000 per award for the Ebola response outbreak. Funding is appropriated under the Continuing Appropriations Resolution, 2015, Public Law 113–164, 128 Stat. 1867 (2014). DATES: Anticipated award date is 12/11/ 2014. Application Due Date: 12/1/2014. Project Number is CDC–RFA–GH14– 1418. CDC has waived the Grants.gov electronic submission process for this requirement. Recipients are hereby authorized to submit a paper copy application for (CDC–RFA–GH14– 1418) via Express Mail (i.e. FedEx, UPS, ADDRESSES: PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 or DHL) and send the application via email. Mailed applications must be address to Dionne Bounds, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, telephone (770) 488–2082, or email at DBounds@cdc.gov. The application must include a detailed line-item budget and justification to support the Ebola activities from December 11, 2014 to September 29, 2015. Please download the following to complete the application package: https:// apply07.grants.gov/apply/forms/ sample/SF424_2_1-V2.1.pdf— Application Package; https:// www.cdc.gov/od/pgo/funding/docs/ CertificationsForm.pdf—Certifications; https://www.cdc.gov/od/pgo/funding/ grants/Budget_Preparation_Guidelines_ 8-2-12.docx—CDC–PGO Budget Guidelines; https://apply07.grants.gov/ apply/forms/sample/SF424A-V1.0.pdf— SF–424A Budget Information. All applications must be submitted to and received by the Grants Management Officer (GMO) no later than 11:59 p.m. EST on December 1, 2014 and please provide the GMO a PDF version of the application by email to the following email address: ogsghebolaresponse@ cdc.gov subject line: CDC–RFA–GH14– 1418. Applicants will be provided with the Funding Opportunity Announcement (FOA) and additional application submission guidance via email notification. Applicants may contact the POCs listed with questions regarding the application process. FOR FURTHER INFORMATION CONTACT: For programmatic or technical assistance: Kawi Mailutha, Project Officer, Department of Health and Human Services, Centers for Disease Control and Prevention, 1600 Clifton Rd. MS E–29, Atlanta, GA 30333, Telephone: 404–639–8093, E-Mail: KMailutha@cdc.gov. For financial, awards management, or budget assistance: Dionne Bounds, Grants Management Officer, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, Telephone (770) 488–2082, Email: DBounds@cdc.gov. SUPPLEMENTARY INFORMATION: The purpose of this notice is to solicit applications from eligible Ministries of Health and their bona fide agents to quickly arrest the spread of the Ebola virus in West Africa and contain the disease as quickly as possible. The funding will support the impacted countries and the surrounding countries to combat this health crisis. This funding will target the following countries: Liberia, Sierra Leone, Guinea, E:\FR\FM\31OCN1.SGM 31OCN1

Agencies

[Federal Register Volume 79, Number 211 (Friday, October 31, 2014)]
[Notices]
[Pages 64799-64800]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-25887]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Bijan Ahvazi, Ph.D., National Institutes of Health: Based on the 
report of an investigation conducted by the National Institutes of 
Health (NIH) and additional analysis by ORI in its oversight review, 
ORI found that Dr. Bijan Ahvazi, former Director of the Laboratory of 
X-ray Crystallography, National Institute of Arthritis and 
Musculoskeletal and Skin Diseases (NIAMS), NIH, engaged in research 
misconduct in research supported by the Intramural Program at NIAMS, 
NIH.
    ORI found that Respondent engaged in research misconduct by 
falsifying data related to or in the following published papers:
    1. Ahvazi, B., Boeshans, K.M., Idler, W., Baxa, U., & Steinert, 
P.M. ``Structural basis for the coordinated regulation of 
transglutaminase 3 by guanine nucleotides and calcium/magnesium.'' J. 
Biol. Chem. 279(8):7180-92, 2004 Feb 20 (withdrawn) (hereinafter ``JBC 
2004a'')
    2. Ahvazi, B., Boeshans, K.M., & Steinert, P.M. ``Crystal structure 
of transglutaminase 3 in complex with BMP: Structural basis for 
nucleotide specificity.'' J. Biol. Chem. 279:26716-25, 2004 (withdrawn) 
(hereinafter ``JBC 2004b'')
    3. Ahvazi, B., Boeshans, K.M., Idler, W.,& Cooper, A.J.L. ``Crystal 
structure of transglutaminase 3-cystamine complex: Binding of two 
cystamines to the nucleotide-binding pocket. M6:06060, Submitted to J. 
Biol. Chem., 2006 (rejected) (hereinafter ``JBC 2006'').
    Specifically, ORI finds that Respondent:
    1. Falsely labeled Figure 3A in JBC 2004b representing an 
isothermal calorimetric titration (ITC) experiment using guanine 
monophosphate (GMP) and transglutaminase 3 (TGase 3) when the figure 
was actually a relabeled version of an unrelated experiment that 
Respondent previously published as Figure 1A in JBC 2004a.
    2. falsified Figure 4B, Figure 4C, and Figure 6D in JBC 2004b and 
Figure 5E in JBC 2006, by altering the original data in the following 
ways to represent the desired experiment:

a. Falsified Figure 4B in JBC 2004b, by adding multiple data points to 
titration curves for four different concentrations of TGase 3 bound by 
different concentrations of tagged GTP[gamma]S and deleting two (2) 
outlying data points from one of the curves
b. falsified Figure 4C in JBC 2004 b, representing a competition assay 
for the release of tagged GTP[gamma]S bound to TGase 3, by (1) falsely 
claiming that the release of the tagged nucleotide occurred with the 
addition of untagged GMP, when the result was from an assay using 
untagged GDP, (2) adding additional data points onto the titration 
curves, and (3) altering the scale of the abscissa
c. falsified Figure 6D in JBC 2004b, by using the false Figure 4B to 
also represent an additional competition experiment using unmodified 
nucleotide analog compounds and

[[Page 64800]]

ATP; specifically, Respondent (1) falsified the units and labels of the 
axes, (2) falsified the labels of the curves, and (3) vertically 
inverted the curves
d. falsified Figure 5E in the JBC 2006 manuscript, representing a 
competition experiment for the release of tagged GTP[gamma]S bound to 
TGase 3 with the addition of cystamine, when the actual experiment was 
a competition experiment with the addition of untagged nucleotides.

    Dr. Ahvazi has entered into a Voluntary Settlement Agreement 
(Agreement) and has voluntarily agreed for a period of two (2) years, 
beginning on October 7, 2014:
    (1) To have his U.S. Public Health Service (PHS) research 
supervised and to notify any employer(s)/institution(s) at which he may 
participate in PHS funded projects of the terms of his supervision; 
Respondent agrees that prior to the submission of an application for 
PHS support for a research project on which the Respondent's 
participation is proposed and prior to Respondent's participation in 
any capacity on PHS-supported research, Respondent shall ensure that a 
plan for supervision of Respondent's duties is submitted to ORI for 
approval; the supervision plan must be designed to ensure the 
scientific integrity of Respondent's research; Respondent agrees that 
he shall not participate in any PHS-supported research until such a 
supervision plan is submitted to and approved by ORI; Respondent agrees 
to maintain responsibility for compliance with the agreed upon 
supervision plan;
    (2) that any institution employing him to work on PHS-supported 
projects shall submit, in conjunction with each application for PHS 
funds, or report, manuscript, or abstract involving PHS-supported 
research in which Respondent is involved, a certification to ORI that 
the data provided by Respondent are based on actual experiments or are 
otherwise legitimately derived and that the data, procedures, and 
methodology are accurately reported in the application, report, 
manuscript, or abstract; and
    (3) to exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-25887 Filed 10-30-14; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.